摘要
利用酶联免疫法对 16 8例 Graves′病患者、36例桥本氏甲状腺炎患者、32例亚急性甲状腺炎患者和35例单纯性甲状腺肿患者和 2 6例正常人测定血清中可溶性细胞间粘附分子 (s ICAM- 1)和可溶性血管粘附分子(s VCAM- 1)含量。结果以上五组 s ICAM- 1依次为 110 5 .1± 10 6 .7ng/ ml、 95 0 .2 3± 310 .5 ng/ m l、786 .2 3±46 2 .4ng/ ml、 2 96 .2± 148.15 ng/ ml、34 2 .5± 2 5 0 .2 ng/ ml。 s VCAM- 1依次为 176 0 .6± 40 3.7ng/ m l、12 31.7±110 .6 ng/ ml;113.2± 143.5 9ng/ ml;941.3± 95 .4ng/ ml;6 6 1.19± 32 0 .78ng/ m l。说明不同的甲状腺疾病患者 ,其血清中粘附分子含量变化不同 。
The changes of sICAM 1 and sVCAM 1 of serum levels in 168 patients with Graves′ disease,36 patints with Hashimoto′s thyroiditis,32 patients with subacute thyroiditis,35 patients Euthyroid nodular goiter and 26 normal subjects were determined by a highly sensitive enzyme linked immunosorbent assay(ELISA) The result of sICAM 1 in serum respectively was 1105 1±106 7ng/ml in Graves′ group,950 23±310 5ng/ml in Hashimoto′s thyroiditis,786 23±462 4ng/ml in subacute thyroiditis,296 2±148 15ng/ml in Euthyroid nodular goiter and 342 5±250 2ng/ml in normal control The sVCAM 1 levels in five groups respectively was 1760 6±403 7ng/ml in Graves′ group,1231 7±110 6ng/ml in Hashimoto′s thyroiditis,113 2±143 59ng/ml in subacute thyroiditis,941 3±95 4ng/ml in Euthyroid nodular goiter and 661 19±320 78ng/ml in normal control The conclusion showed that there is a difference concentration of sICAM 1 and sVCAM 1 in serum with thyroid diseases
出处
《山东医药》
CAS
北大核心
2001年第16期8-9,共2页
Shandong Medical Journal
基金
山东省优秀中青年科学家专项基金资助项目 (963 842 2 2 )
